ERBB2 and neoplasm: One patient with a dual c-MYC and HER2 highly co-amplified tumour continued treatment for 32 weeks which may hint at enhanced efficacy of ibrutinib in a co-amplified tumour; however, most patients progressed after 2 cycles (57%).